Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Citalopram for the Prevention of Depression (PICCO)

This study has been completed.
Sponsor:
Collaborators:
Ontario HIV Treatment Network
Schering-Plough
CIHR Canadian HIV Trials Network
Information provided by (Responsible Party):
Marina Klein, McGill University Health Center
ClinicalTrials.gov Identifier:
NCT00317746
First received: April 21, 2006
Last updated: April 4, 2014
Last verified: April 2014

April 21, 2006
April 4, 2014
November 2006
March 2012   (final data collection date for primary outcome measure)
  • The primary outcome is the average proportion of PEG-IFN and ribavirin doses received in participants receiving citalopram compared with placebo [ Time Frame: week 24 ] [ Designated as safety issue: No ]
  • A second major objective is to compare arms with respect to the rate of moderate-to-severe depressive symptoms during the first 24 weeks of therapy. [ Time Frame: week 12 and week 24 ] [ Designated as safety issue: No ]
  • Primary Outcome, the average proportion of PEG-IFN and ribavirin doses received in participants receiving citalopram compared with placebo at 24 weeks.
  • A second major objective is to compare arms with respect to the rate of moderate-to-severe depressive symptoms during the first 24 weeks of therapy.
Complete list of historical versions of study NCT00317746 on ClinicalTrials.gov Archive Site
  • Secondary measures will assess impact of citalopram versus placebo on anxiety, neurocognitive function, quality of life and adherence to therapy. HCV and HIV control will also be examined. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Substudies aimed at understanding the pathogenesis of neuropsychiatric side effects and neurocognitive function in this population will be performed. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Secondary measures, Will assess impact of citalopram vs. placebo on anxiety, neurocognitive function, quality of life and adherence to therapy. HCV and HIV control will also be examined.
  • Substudies aimed at understanding the pathogenesis of neuropsychiatric side effects and neurocognitive function in this population will be performed.
Not Provided
Not Provided
 
Trial of Citalopram for the Prevention of Depression
A Randomized, Placebo Controlled Trial of Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Co-infected Individuals Initiating Pegylated Interferon/Ribavirin Therapy

With the improved prognosis of human immunodeficiency virus (HIV) infection, end stage liver disease due to hepatitis C (HCV) now represents a major cause of morbidity and mortality in people with HIV. Treatment for HCV has become increasingly important as a means of preventing the consequences of chronic HCV infection. Paradoxically, co-infected patients have low rates of treatment initiation and completion in large part because they have a high risk of developing neuropsychiatric symptoms while receiving PEG-interferon (PEG-IFN). There are a large number of co-infected individuals in Canada who could benefit from HCV therapy if tolerability could be improved. This trial will address whether prophylactic use of antidepressants in HIV-HCV infected patients initiating HCV therapy can prevent the development of neuropsychiatric side effects and thus permit more patients to receive full treatment for HCV.

Trial design:

This study is a Canadian multicentre randomized, double-blind placebo controlled trial. We will evaluate whether prophylactic citalopram compared to symptomatic treatment of depression can significantly increase the amount of HCV therapy received in co-infected patients during the first 24 weeks. Post study follow-up will extend until 6 months after cessation of HCV therapy (up to 72 weeks) to capture information on SVR (sustained virologic response) for HCV. 76 patients will be randomized in a 1:1 ratio to citalopram or placebo. Patients will be stratified by study centre and HCV genotype. Citalopram (or placebo) will begin 3 weeks before HCV treatment at an initial dose of 10 mg per day then be increased to 20 mg per day after one week and continued throughout treatment with PEG-IFN/ribavirin (up to 48 weeks) and then tapered to discontinuation at completion of HCV therapy. The management of depression emerging in study participants is mandated in the protocol to ensure that the original treatment assignments remain blinded while allowing for all subjects to remain in the study and mimics what would take place in clinical practice.

Analysis:

The analyses will follow the intention-to-treat approach. Random regression modelling will be employed to analyse longitudinal data on adherence to prescribed PEG-IFN and ribavirin dosage at weeks 12 and 24. Survival analyses will be used to compare the two treatment groups with respect to the time to the development of depressions.

Implications:

Prophylactic antidepressants may not only prevent overt depression but may also diminish the development of sub-clinical depressed mood. Effective prevention of a broad range of neuropsychiatric symptoms by use of citalopram has the potential to diminish morbidity associated with PEG-IFN treatment and consequently allow a greater number of patients to complete full therapy. In addition, such an approach may help patients remain adherent to their HIV therapy during the course of HCV treatment which could have long-term personal and public health implications by preventing the emergence of HIV resistance. Furthermore, if shown to be an effective strategy for preventing neuropsychiatric symptoms, treatment for HCV may become more accessible to the large number of patients who may not have ready access to the frequent and intensive psychiatric monitoring, necessary for the early detection and treatment of depression that manifests on PEG-IFN.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Depression
  • HIV Infections
  • Hepatitis C
Drug: Citalopram
  • Placebo Comparator: Placebo
    Placebo + PEG-interferon-alfa2b + ribavirin
  • Experimental: Citalopram
    Citalopram + PEG-interferon-alpha2b + ribavirin
    Intervention: Drug: Citalopram
Klein MB, Lee T, Brouillette MJ, Sheehan NL, Walmsley S, Wong DK, Conway B, Hull M, Cooper C, Haidar S, Vezina S, Annable L, Young S, Zubyk W, Singer J. Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial. HIV Clin Trials. 2014 Jul-Aug;15(4):161-75. doi: 10.1310/hct1504-161.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
76
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV+ adults with chronic HCV infection requiring therapy and with no contraindications to PEG-IFN/ribavirin will be enrolled.

Exclusion Criteria:

  • Subjects with prior suicide attempt, active depression, treatment with antidepressants within 6 months of study entry or with other psychiatric disorders will be excluded.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00317746
CTN194, Schering #2229
Yes
Marina Klein, McGill University Health Center
Marina Klein
  • Ontario HIV Treatment Network
  • Schering-Plough
  • CIHR Canadian HIV Trials Network
Principal Investigator: Marina B Klein, MD Immunodeficiency Service Montreal Chest Institute
McGill University Health Center
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP